HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sales & Earnings In Brief

This article was originally published in The Tan Sheet

Executive Summary

Costs eat into NBTY income: Despite a 21.9 percent increase in net sales to $651.7 million in the April-June period, NBTY reports flat net income due to higher costs and expenses. Net income in the firm's fiscal 2009 third quarter was $45.9 million, compared to $45.5 in the year-ago period, NBTY said July 27. The supplement manufacturer and retailer experienced a significantly higher cost of sales - up 36.9 percent to $359.2 million - and a $10.1 million charge for discontinued information technology projects "determined to be ineffective and uneconomical" and $4 million in legal expenses from the antitrust case associated with NBTY's purchase of U.K. retailer Julian Graves. However, advertising, promotion and catalog costs fell 34 percent to $23.6 million. CEO Scott Rudolph said in a same-day earnings call that he expects the private-label share of NBTY's sales to increase. "Because private-label sales traditionally have lower gross profits, our overall gross profit margin should decrease," he said. President and Chief Financial Officer Harvey Kamil said the gross margins and increased productivity in the third quarter appear to be sustainable and are more indicative of the Ronkonkoma, N.Y.-based firm's future performance than the first half of fiscal 2009, when net income growth suffered. High material costs hurt NBTY's bottom line in previous quarters, though Rudolph said the volatility in material pricing is beginning to stabilize (1"The Tan Sheet" April 27, 2009). The Julian Graves acquisition has been provisionally approved, but the execs said that following the U.K. Competition Commission's final decision - expected by Sept. 3 - it could take up to nine months to integrate the chain (2"The Tan Sheet" July 27, 2009, In Brief)

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS136568

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel